← Oncology Approval Tracker

FDA DECISION ·

Imfinzi + Padcev

durvalumab and enfortumab vedotin-ejfv · AstraZeneca (Imfinzi)

FDA approvalNew or expanded indicationBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Neoadjuvant durvalumab with enfortumab vedotin-ejfv, followed after radical cystectomy by adjuvant durvalumab alone, for adults with muscle-invasive bladder cancer who cannot receive or have refused cisplatin-based chemotherapy.

SUPPORTING DATA

Evidence behind the decision

Study
VOLGA: randomized, open-label, three-arm trial enrolling 695 surgical candidates.
Key result
Against cystectomy alone, event-free survival hazard ratio was 0.51 (95% CI 0.38-0.67); overall-survival hazard ratio was 0.58 (95% CI 0.40-0.83).
Safety to report
FDA highlights immune-mediated toxicity, infusion reactions, rash, laboratory abnormalities and peripheral neuropathy.
Evidence limits
The comparator was surgery alone, not another approved perioperative drug regimen. These findings do not establish superiority over that regimen.

LAMPGEN ANALYSIS

Why it matters

Adds a perioperative option for the specified cisplatin population. Eligibility and postoperative treatment differ from other approved bladder regimens.

What research teams should watch

Coordinate screening, cisplatin eligibility or refusal documentation, surgery scheduling, perioperative assessments and postoperative handoffs.

PRIMARY RECORDS

Sources